Highlights of This Issue 1023

SMALL MOLECULE THERAPEUTICS

1025  LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma
Linlin Yang, Bhavna Kumar, Changxian Shen, Songzhu Zhao, Dukagjin Blakaj, Tianyun Li, Mitchell Romito, Theodoros N. Teknos, and Terence M. Williams

1036  SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer
Shweta Joshi, Alok R. Singh, Kevin X. Liu, Timothy V. Pham, Muameral Zulcic, Dylan Skola, Hyun Bae Chun, Christopher K. Glass, Guillermo A. Morales, Joseph R. Garlich, and Donald L. Durden

1045  Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma
Yang Yu, Yanling Zhao, Yihui Fan, Zhenghu Chen, Hui Li, Jiaxiong Lu, Kevin Guo, Sarah E. Woodfield, Sanjeev A. Vasudevan, Jianhua Yang, and Jed G. Nuchtern

1057  Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin
Livia Elena Sima, Bakhtiyor Yakubov, Sheng Zhang, Salvatore Condello, Arabela A. Grigorescu, Nkechiyere G. Nwani, Lan Chen, Gary E. Schiltz, Constandina Arvanitis, Zhong-Yin Zhang, and Daniela Matei

LARGE MOLECULE THERAPEUTICS

1069  A Tumor-Peptide–Based Nanoparticle Vaccine Elicits Efficient Tumor Growth Control in Antitumor Immunotherapy
Carolin Heße, Sebastian Kollenda, Olga Rotan, Eva Pastille, Alexandra Adamczyk, Christina Wenzek, Wiebke Hansen, Matthias Epplle, Jan Buer, Astrid M. Westendorf, and Torben Knuschke

1081  A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy
Pottayil G. Sasikumar, Raghveer K. Ramachandra, Srinivas Adurthi, Amit A. Dhudashiya, Sureshkumar Vadlamani, Koneswararao Vemula, Srihariaburu Vunnum, Leena K. Satyam, Dodderi S. Samiulla, Krishnaprasad Subbarao, Rashmi Nair, Rajeev Shrimlal, Nagaraj Gowda, and Murali Ramachandra

1092  Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effecter Bispecific Design
Nam-Kyung Lee, Yang Su, Scott Bidlingmaier, and Bin Liu

1104  Discovery of A Novel EGFR-Targeting Antibody–Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies
Kaijie He, Jianyan Xu, Jindong Liang, Jiahua Jiang, Mi Tang, Xin Ye, Zhebin Zhang, Lei Zhang, Beibei Fu, Yan Li, Chang Bai, Liangshan Zhang, and Weikang Tao

CANCER BIOLOGY AND TRANSLATIONAL STUDIES

1115  Neutralization of BCL-2/XI Enhances the Cytotoxicity of T-DM1 In Vitro

1127  Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966
Tae Jin Lee, Mitra Nair, Yeshavanh Banasavadi-Siddgowda, Joseph Liu, Tejaswini Nallanagulagari, Alena Cristina Jaimie-Ramirez, Jeffrey Yinhua Guo, Haroon Quadri, Jianying Zhang, Kurt H. Bockhorst, Manish K. Aghi, W. Shawn Carbonell, Balveen Kaur, and Ji Young Yoo
ABOUT THE COVER

The BCL-2/XL pro-survival proteins compromise the effectiveness of cancer therapies. Here, Zoeller and colleagues provide in vivo evidence that neutralization of BCL-2/XL via navitoclax/ABT-263 enhances the cytotoxic effectiveness of the HER2-targeted antibody-drug conjugate T-DM1. To assess the pathological responses associated with combined treatments, the authors performed specialized histological staining. The cover represents microscopic analysis of a Masson’s trichrome stained patient-derived xenograft treated with T-DM1 and navitoclax/ABT-263, and demonstrates substantial elimination of the tumor cells (red) and the emergence of a reactive stroma (blue). For more information, please see the article starting on page 1115.